Last updated: February 20, 2026
What is NDC 42385-0962?
NDC 42385-0962 corresponds to Amikacin Injekt (Amikacin Sulfate), a broad-spectrum aminoglycoside antibiotic used primarily for serious bacterial infections, including those caused by multi-drug resistant organisms. It is administered intramuscularly or intravenously.
Market Size and Demand
Current Market Overview
The global antibiotic market was valued at approximately USD 54.6 billion in 2022. The segment for injectable antibiotics, including aminoglycosides like amikacin, represents roughly 20% of this, translating to USD 10.9 billion. The market for amikacin remains steady due to its critical role in hospital settings, especially for resistant infections.
Key Global Markets
| Region |
Market Share |
Estimated Market Value (2022) |
Growth Rate (CAGR 2023-2028) |
| North America |
40% |
USD 4.36 billion |
2.5% |
| Europe |
25% |
USD 2.73 billion |
2.2% |
| Asia-Pacific |
25% |
USD 2.73 billion |
5.3% |
| Rest of World |
10% |
USD 1.09 billion |
3.0% |
Drivers of Market Demand
- Increasing prevalence of multi-drug resistant infections (source: CDC, WHO).
- Growth in hospital-acquired infections.
- Expansion of intensive care units globally.
- Limited pipeline of new aminoglycosides, maintaining current drugs' relevance.
Competitive Landscape
Leading manufacturers include:
- Hikma Pharmaceuticals
- Sandoz (Novartis)
- Cipla
- Teva Pharmaceuticals
These companies account for approximately 70% of global supply.
Regulatory Environment
- USFDA approval remains robust.
- Some markets facing shortages due to manufacturing disruptions.
- Generic production dominates, with limited branded options.
Price Projections (2023-2028)
Current Pricing Dynamics
- Average wholesale acquisition cost (WAC) for amikacin injections in the U.S.: USD 12 - USD 20 per 50 mg vial.
- Prices vary based on dosage and packaging.
Future Price Trends
| Year |
Price Range (per 50 mg vial) |
Drivers |
| 2023 |
USD 12 - USD 20 |
Stable supply, ongoing demand |
| 2024 |
USD 13 - USD 22 |
Slight inflation, regulation impacts |
| 2025 |
USD 14 - USD 24 |
Potential supply constraints, increased manufacturing costs |
| 2026 |
USD 15 - USD 26 |
Emerging shortages, demand rise in Asia-Pacific |
| 2027 |
USD 16 - USD 28 |
Continued resistance to alternative treatments |
| 2028 |
USD 17 - USD 30 |
Market consolidation, patent expiries for competitors |
Pricing Considerations
- Pricing will likely be influenced by manufacturing costs, regulatory changes, and global demand.
- Hospitals may experience price increases due to shortages or supply chain issues.
- Generic dominance limits significant price hikes but inflationary pressures remain.
Strategic Insights
- Market Opportunity: Demand persists due to the critical role of amikacin in resistant infections.
- Supply Risks: Manufacturing disruptions and regulatory hurdles could cause shortages, impacting prices.
- Market Entry: Opportunities exist for biosimilar development, though regulatory pathways for generic injectable antibiotics are complex.
- Pricing Power: Limited, due to the dominance of generics, but scarcity can temporarily increase prices.
Key Takeaways
- The amikacin market is stable but growth is moderate, expected at a CAGR of 2.2-5.3%.
- Prices are projected to rise gradually from USD 12 to USD 30 per vial over the next five years.
- The primary drivers include resistance patterns, hospital demand, and manufacturing dynamics.
- Market risks include manufacturing disruptions and regulatory changes affecting supply.
Frequently Asked Questions
1. Will the price of NDC 42385-0962 increase significantly in the next five years?
Prices are expected to increase gradually, influenced by supply constraints and demand for resistant-infection treatments, but large jumps are unlikely due to generic competition.
2. Is there potential for new formulations or patents?
Currently, no new formulations are in advanced development stages; patent expiries for existing formulations could lead to increased generic competition.
3. How does resistance impact the market for amikacin?
Rising resistance enhances demand for amikacin, but limits the effectiveness of other antibiotics, potentially elevating its value.
4. Are shortages imminent for this drug?
Supply disruptions have been reported in select regions; shortages could drive prices higher temporarily.
5. What are the key regulatory hurdles for market entry or expansion?
Manufacturers must demonstrate bioequivalence and meet stringent safety standards, with additional approval processes in certain regions.
References
[1] MarketsandMarkets. (2022). Antibiotics Market by Product, Route of Administration, Distribution Channel, and Region - Global Forecast to 2028.
[2] Centers for Disease Control and Prevention (CDC). (2021). Antibiotic Resistance Threats in the United States.
[3] WHO. (2023). Global action plan on antimicrobial resistance.
[4] IQVIA. (2022). Global Infectious Disease Pharmaceuticals Market Data.
[5] U.S. Food and Drug Administration (FDA). (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
